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SUMMARY

Gain-of-function mutations in isocitrate dehydrogenase 1 (IDH1) occur in multiple types of human
cancer. Here, we show that these mutations significantly disrupt NADPH homeostasis by consuming
NADPH for 2-hydroxyglutarate (2-HG) synthesis.
Cells respond to 2-HG synthesis, but not exogenous
administration of 2-HG, by increasing pentose phosphate pathway (PPP) flux. We show that 2-HG production competes with reductive biosynthesis and
the buffering of oxidative stress, processes that
also require NADPH. IDH1 mutants have a decreased
capacity to synthesize palmitate and an increased
sensitivity to oxidative stress. Our results demonstrate that, even when NADPH is limiting, IDH1 mutants continue to synthesize 2-HG at the expense of
other NADPH-requiring pathways that are essential
for cell viability. Thus, rather than attempting to
decrease 2-HG synthesis in the clinic, the consumption of NADPH by mutant IDH1 may be exploited as
a metabolic weakness that sensitizes tumor cells
to ionizing radiation, a commonly used anti-cancer
therapy.
INTRODUCTION
There are three subtypes of isocitrate dehydrogenase (IDH) that
vary according to their cellular location and NADP+ or NAD+ dependency (Dang and Su, 2017). Each subtype oxidatively decarboxylates isocitrate to alpha-ketoglutarate under most normal
physiological conditions, but the NADP+-dependent IDH1 is
uniquely situated in the cytosol, peroxisomes, and endoplasmic
reticulum, whereas the NADP+-dependent IDH2 and the NAD+dependent IDH3 are in the mitochondrial matrix (Geisbrecht
and Gould, 1999; Lewis et al., 2014; Margittai and Bánhegyi,
2008). The cellular location of the IDH1 and IDH2 enzymes is
particularly important because NADPH does not have protein
transporters to cross the inner mitochondrial membrane (Pollak

et al., 2007). However, both the cytosol and the mitochondria
have essential NADPH demands. In the cytosol, NADPH is
needed for the reductive biosynthesis of palmitate and cholesterol (Lunt and Vander Heiden, 2011). In the cytosol and the mitochondria, NADPH is a required cofactor for the glutathione and
thioredoxin systems to neutralize reactive oxygen species that
result from oxidative stress (Ren et al., 2017). Thus, each cellular
compartment must independently balance their NADPH production and consumption rates.
In this study, we were interested in assessing changes in
NADPH homeostasis that result from a mutation in IDH1
substituting an arginine for a histidine at codon 132 (R132H).
This IDH1 R132H mutation is prevalent in several forms of human cancer, such as low-grade gliomas and secondary
glioblastomas (Cohen et al., 2013; Yan et al., 2009). Importantly, not only does the R132H mutation result in the loss of
the enzyme’s ability to produce NADPH, it also confers a gain
of enzyme function that consumes NADPH (Dang et al.,
2009). Wild-type IDH1 reduces NADP+ to NADPH while converting isocitrate to alpha-ketoglutarate. Mutant IDH1, on
the other hand, oxidizes NADPH to NADP+ while converting alpha-ketoglutarate to the metabolite 2-hydroxyglutarate
(2-HG). Notably, 2-HG accumulates to millimolar concentrations in the media of IDH1 mutant cells as well as in some
IDH1 mutant tumors (Dang et al., 2009), suggesting that its synthesis requires a large amount of NADPH. Here, we sought to
determine the effect that this metabolic demand for NADPH
has on other NADPH-requiring pathways, particularly when
NADPH is limiting.
We considered two potential metabolic consequences of
the NADPH demands imposed by 2-HG synthesis. One possibility is that consuming NADPH for 2-HG synthesis results in a
shortage of NADPH. Indeed, it has been speculated that using
NADPH for 2-HG synthesis further contributes to an NADPH
deficit due to impaired wild-type IDH1 activity, which is a major source of NADPH in some cells (Atai et al., 2011; Losman
and Kaelin, 2013). We predicted that such a deficit in NADPH
could limit the activity of other NADPH-requiring reactions,
such as those involved in reductive biosynthesis and the buffering of oxidative stress. An alternative possibility is that
cells increase their production of NADPH to compensate for
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impaired IDH1 wild-type activity and 2-HG synthesis. Directing
more glucose carbon through the pentose phosphate
pathway (PPP), for example, allows for increased production
of NADPH.
In this work, we evaluated HCT116 human colorectal carcinoma cells with a knockin heterozygous R132H mutation at
the IDH1 locus. Given that tumor-associated IDH mutations
are usually observed to occur in the heterozygous state in
the clinic, these cells mimic those found in the tumors of patients. We also extended the scope of our study by using
immortalized human astrocytes with transgenic IDH1 R132H,
which displayed a comparable metabolic phenotype. We
found that although both of these cell lines do increase their
production of NADPH by the PPP to support 2-HG synthesis,
the NADPH produced is insufficient for all NADPH-requiring
reactions, particularly under conditions of oxidative stress.
Reductive biosynthesis, glutathione reductase, and 2-HG synthesis therefore cannot all be adequately supported. Interestingly, cells continue to synthesize 2-HG even though it directs
NADPH away from other reactions that are required for cell
viability.
RESULTS
IDH1 Mutants Can Synthesize 2-HG from Glucose or
Glutamine Carbon
We aimed to understand the metabolic flexibility that IDH1
mutant cells have in synthesizing 2-HG. We first considered
the carbon source from which 2-HG is synthesized. Although
glutamine has been primarily considered as the major precursor
to 2-HG (Dang et al., 2009), we found that 2-HG can also be produced from glucose. When HCT116 cells were cultured in media
without glutamine, they still produced 2-HG at high levels (Figure 1A). Moreover, experiments tracking uniformly labeled 13C
glutamine (U-13C glutamine) or uniformly labeled 13C glucose

Figure 1. Carbon for 2-HG Synthesis Can Be
Derived from Glucose or Glutamine
(A) Relative level of 2-HG in wild-type HCT116 cells
grown with 25 mM glucose and no glutamine (other
than that from FBS), or 4.5 mM glutamine and no
glucose (other than that from FBS). Irrespective of
condition, the cells synthesized 2-HG.
(B) Isotopologue distribution pattern of 2-HG after
HCT116 R132H/+ cells were labeled with U-13C
glutamine, with no glucose (other than that from
FBS) present in the culture media.
(C) Isotopologue distribution pattern of 2-HG after
HCT116 R132H/+ cells were labeled with U-13C
glucose, with no glutamine (other than that from
FBS) present in the culture media.
(D) Isotopologue distribution pattern of 2-HG after
HCT116 R132H/+ cells were labeled with U-13C
glucose in the presence of 4.5 mM glutamine. Data
shown are mean values ± SD (n = 3).

(U-13C glucose) showed that both are
used as a source of 2-HG carbon (Figures
1B–1D). These data suggest that IDH1
mutants have flexibility with respect to the carbon source of
2-HG and are consistent with previous reports (Izquierdo-Garcia
et al., 2015).
Increased PPP Flux in IDH1 Mutants
Given the observed flexibility in carbon for 2-HG synthesis,
we turned our attention to NADPH as a potential limiting
factor (Figure 2A). Not only is NADPH required to synthesize
2-HG from alpha-ketoglutarate, IDH1 mutants also have
reduced NADPH production due to impaired wild-type IDH1
activity (Bleeker et al., 2010). For both HCT116 cells and astrocytes, we measured a significantly decreased NADPH/NADP+
ratio in IDH1 mutants relative to wild-type controls (Figures
2B and 2C). We next set out to determine whether cells responded to this altered ratio by increasing NADPH production.
Since IDH1 is localized to the cytosol, we focused on the PPP,
which is a major source of cytosolic NADPH (Lewis et al.,
2014). To assess the flux of the PPP, we first applied a previously established method using liquid chromatography/mass
spectrometry (LC/MS) to trace 13C labels from 1,2-13C2 glucose
(Lee et al., 1998; Li et al., 2014). When 1,2-13C2 glucose is
metabolized directly through glycolysis, without entering the
PPP, lactate containing two 13C labels is produced. When
1,2-13C2 glucose is metabolized through the PPP, in contrast,
an oxidative decarboxylation reaction removes the 13C label
on the first position of glucose. This produces ribulose 5-phosphate containing one 13C label, which then can be inserted
back into glycolysis via the non-oxidative reactions of the
PPP. The result is lactate containing only a single 13C label
(Figure 3A). The ratio of singly labeled lactate (the M+1 isotopologue) to doubly labeled lactate (the M+2 isotopologue) represents the ratio of flux through the PPP to flux directly through
glycolysis.
We found a statistically significant difference in lactate labeling from wild-type HCT116 control cells and IDH1 mutants
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(Figure 3B). By media analysis, we determined that IDH1 mutants
have a significantly higher rate of glucose uptake relative to wildtype controls (Figure 3C). We then calculated PPP flux by using
the difference in lactate labeling normalized by glucose uptake.
We found that the IDH1 mutants have a 40% increase in PPP
flux relative to wild-type controls (Figure 3D; Table S1). These
data are consistent with the 40% increase measured in the concentration of the PPP intermediate 6-phosphogluconate (6PG) in
IDH1 mutants relative to wild-type cells (Figure 3E) and puts the
PPP flux in the same order of magnitude as the rate of 2-HG synthesis (Table S1). We also note that increased PPP flux in IDH1
mutants relative to wild-type cells was determined to be independent of fetal bovine serum (FBS) concentration (Figures
S1A–S1C).
A limitation of using the lactate-labeling method above
to assess PPP flux is that it is not specific to the oxidative
phase of the pathway, which is where NADPH is produced.
One possibility is that ribulose 5-phosphate produced by
the oxidative phase of the PPP does not re-enter glycolysis
to become lactate. In some cancers, for example, the oxidative phase and the non-oxidative phase of the PPP may
run in the same direction toward ribose 5-phosphate production (Liu et al., 2010). To specifically assess the rate of NADPH
production by the oxidative phase of the PPP, we performed
kinetic flux profiling as has been described previously
(Yuan et al., 2008). Cells were given U-13C glucose and incorporation of label from glucose 6-phosphate into 6PG
was measured as function of a time (Figures S1D and S1E).
Data from kinetic flux profiling were consistent with the data
from lactate labeling above, showing an 44% increase in
flux of the oxidative PPP in IDH1 mutants relative to wildtype cells.
Assessing Malic Enzyme Flux in IDH1 Mutants
Classically, the oxidative PPP is thought to be the primary source
of cytosolic NADPH (Fan et al., 2014). The malic enzyme (ME),
however, also produces NADPH, and therefore we sought to
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Figure 2. Evaluating NADPH in IDH1 Mutant
Cells
(A) In the cytosol, NADPH is required for 2-HG
synthesis, for reductive biosynthesis (e.g., fatty
acid synthesis), and to neutralize reactive oxygen
species (e.g., by the glutathione system).
(B and C) The ratio of NADPH to NADP+ decreases in HCT116 (B) and astrocyte R132H (C)
mutants compared to wild-type (WT) cells. Ratios
were determined by using a colorimetric assay.
Data shown are mean values ± SD (n = 3).
**p value < 0.01.

evaluate whether ME flux increased in
IDH1 mutants. Cells were given U-13C
glutamine, and lactate labeling, which represents ME activity, was compared between wild-type cells and IDH1 mutants
(Figure S2A). Although our analysis cannot
distinguish between the cytosolic and
mitochondrial subtypes of ME, the data did not support an overall increase in ME activity in IDH1 mutants (Figure S2B).
Inhibiting 2-HG Synthesis Reduces PPP Flux
To test our hypothesis that PPP flux increases to produce
NADPH in support of 2-HG synthesis, we treated IDH1 mutants
with an inhibitor of 2-HG and measured changes in PPP activity.
We pharmacologically inactivated R132H-IDH1 with the selective inhibitor AGI-5198 (Rohle et al., 2013), which we found to
decrease intracellular 2-HG levels by 70% (Figure 4A). We
exposed cells to 0.2 mM AGI-5198 (dissolved in DMSO) for
72 hr prior to labeling with 1,2-13C2 glucose. By applying the
same method as above, we measured PPP flux. Although AGI5198 treatment did not completely restore PPP flux to the level
of wild-type cells, it did reduce it significantly (Figure 4B). These
results were consistent with the relative changes in 6PG concentration (Figure 4C). Interestingly, glucose uptake was not
reduced by AGI-5198 treatment (Figure 4D). Since the additional
glucose taken up by IDH1 mutants relative to wild-type cells was
not being directed to the PPP upon AGI-5198 treatment, less of
the carbon was being lost as carbon dioxide due to 6PG dehydrogenase activity. Increased glucose flux through the oxidative
PPP has been shown to decrease lactate excretion (Zhao et al.,
2009), and we therefore speculated that AGI-5198 would increase lactate excretion. Indeed, we measured increased lactate
excretion in cells treated with AGI-5198 (Figure 4E).
Increased PPP Flux Supports the NADPH Demands of
2-HG Synthesis
We next set out to determine whether the increased PPP flux in
IDH1 mutants is to support the NADPH demands of 2-HG synthesis, or whether increased PPP flux is a response to oxidative
stress caused by the presence of 2-HG. Previous studies have
shown that 2-HG is sufficient in itself to induce oxidative stress
(Latini et al., 2003). Thus, to assess potential changes in PPP
flux due to oxidative stress associated with the presence of
2-HG, we exposed wild-type cells to 0.1 mM octyl 2-HG for

Figure 3. IDH1 Mutants Have Increased
PPP Flux
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(A) Schematic showing lactate labeling when
1,2-13C2 glucose is metabolized through glycolysis
directly, and when 1,2-13C2 glucose is metabolized
through the PPP and then fed back into glycolysis.
Red circles correspond to 13C-labeled carbons, and
black circles correspond to unlabeled 12C carbons.
(B) Isotopologue distribution of lactate in wild-type
cells and HCT116 R132H/+. The M+1 isotopologue
is a result of glucose that passed through the PPP.
The M+2 isotopologue corresponds to glucose
that was metabolized to lactate through glycolysis
directly.
(C) Uptake of glucose by wild-type cells and mutant
IDH1 as measured by LC/MS analysis of the media.
(D) Relative PPP flux, as determined by lactate labeling from 1,2-13C2 glucose and glucose uptake.
(E) The PPP intermediate 6-phosphogluconate
(6PG) is increased in IDH1 mutants relative to WT
cells. Data shown are mean values ± SD (n = 3).
*p value < 0.05; ***p value < 0.001.

cellular 2-HG concentration is complicated
because these cells also have decreased
rates of glycolysis and tricarboxylic acid
(TCA) cycle activity (Figure S4B).

D

E

72 hr prior to providing them with 1,2-13C2 glucose. We used the
octyl ester of 2-HG to improve cell permeability (Xu et al., 2011).
The concentration of octyl 2-HG used resulted in intracellular
concentrations of 2-HG that are comparable to those measured
in IDH1 mutants (Figure S3A). No statistically significant change
in PPP flux was measured as a result of octyl 2-HG treatment
(Figure S3B). These data suggest that the changes observed
in IDH1 mutant cells are to support the NADPH demands of
2-HG synthesis, and not to neutralize oxidative stress induced
by the presence of 2-HG.
It is provocative to consider blocking the production of NADPH
by the PPP as a means to inhibit 2-HG synthesis in IDH1 mutants;
however, the accumulation of PPP intermediates negatively regulates glycolysis (Kahana et al., 1960; Parr, 1956). Cells treated with
6-aminonicotinamide, an inhibitor of 6PG dehydrogenase (Tsouko
et al., 2014), do show decreased levels of intracellular 2-HG
(Figure S4A). However, interpreting the cause of the reduced intra-

Expression of Glucose 6-Phosphate
Dehydrogenase Is Not Significantly
Increased in IDH1 Mutants
Under physiological conditions, glucose
6-phosphate dehydrogenase (G6PD) catalyzes the rate-limiting step of the oxidative
PPP and its activity is therefore tightly
regulated as a control point (Jiang et al.,
2014). Given that NADPH competes with
NADP+ in binding G6PD, the NADPH/
NADP+ ratio is a major modulator of
enzyme activity (Berg et al., 2002). A
decreased NADPH/NADP+ ratio (as measured in our IDH1 mutants; Figure 2) is sufficient to activate G6PD activity (Eggleston and Krebs, 1974;
Jiang et al., 2011). G6PD activity has also been shown to be
regulated by expression (Patra and Hay, 2014), and we therefore
performed qPCR to examine its levels. Our analyses did not
reveal a statistically significant difference in expression levels
between wild-type and mutant cells (Figure S5A). We note that
a high NADPH/NADP+ ratio has been reported to result in low
enzyme activity (Eggleston and Krebs, 1974), independent of
expression levels (Patra and Hay, 2014). Thus, although we did
not observe increased expression of G6PD and additional
post-translational mechanisms might be at work (Rao et al.,
2015), our data indicate that allosteric control is increasing
PPP activity in the IDH1 mutants that we examined.
Fatty Acid Synthesis Is Decreased in IDH1 Mutants
Fatty acid synthesis primarily occurs in the cytosol, where
acetyl-CoA units are used to make palmitate (Menendez and
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Figure 4. Effects of AGI-5198 on 2-HG Synthesis, PPP Flux, and Glucose Uptake
(A) AGI-5198 effectively inhibits 2-HG synthesis. HCT116 R132H/+ cells were exposed to either AGI-5198 or vehicle (DMSO) for 72 hr prior to making the
intracellular measurements 24, 36, or 48 hr later.
(B) Relative PPP flux in untreated wild-type control cells, IDH1 mutants treated with AGI-5198, and untreated IDH1 mutants.
(C) Intracellular levels of the PPP intermediate 6PG are consistent with changes observed in PPP flux.
(D) Uptake of glucose from the media is not significantly altered in IDH1 mutants due to AGI-5198 treatment.
(E) Lactate excretion increases when IDH1 mutants are treated with AGI-5198. Data shown are mean values ± SD (n = 3). *p value < 0.05, **p value < 0.01, and
***p value < 0.001.

Lupu, 2007). Other fatty acids are then derived from palmitate
through elongation and desaturation reactions (Cook and
McMaster, 2002). For each molecule of palmitate synthesized,
14 molecules of NADPH are required (Vander Heiden et al.,
2009). Palmitate synthesis is important in rapidly proliferating
cancer cells, such as those studied here, to support the formation of new membranes (Yao et al., 2016a).
In IDH1 mutants, we found that the ratio of NADPH to NADP+
was significantly reduced (Figures 2B and 2C). This led us to hypothesize that the NADPH-dependent synthesis of palmitate
may be limited. We first compared the relative concentration of
palmitate and determined that it was decreased in IDH1 mutants
with respect to wild-type controls (Figure 5A). Because standard
media contains relatively little palmitate, we associated this difference with a change in palmitate synthesis (Yao et al.,
2016a). To more directly test whether the rate of palmitate synthesis was altered, we cultured cells in U-13C glucose for 24 hr
and used LC/MS to measure the labeling pattern of palmitoylcarnitine. Inferring the palmitate labeling pattern from palmitoylcarnitine has been shown to be consistent with analysis of palmitate
directly, but analysis of palmitoylcarnitine is unaffected by
potential palmitate contamination introduced during sample
handling (Yao et al., 2016b). When comparing IDH1 mutants to
wild-type controls, we observed a decrease in the total enrichment of palmitoylcarnitine (Figure 5B). Additionally, we found
that the overall isotopic distribution was shifted toward lighter
m/z in IDH1 mutants. To quantitate these differences, we per-
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formed isotopomer spectral analysis (ISA) by using the convISA
algorithm implemented in MATLAB (Tredwell and Keun, 2015).
Dglucose represents the fractional enrichment of acetyl-CoA
from glucose, and g(t) represents the fractional de novo synthesis of palmitate during 24 or 120 hr of glucose labeling (Table 1).
Although Dglucose was approximately the same between IDH1
mutants and wild-type cells, the fractional de novo synthesis of
palmitate decreased by 20% in IDH1 mutants. ISA data from
120 hr of labeling, which approached isotopic steady state, suggest that differences in the fractional de novo synthesis of palmitate are not a result of differences in proliferation rates and
indicate that palmitoylcarnitine labeling is decreased in IDH1
mutants due to decreased palmitate synthesis.
Given that rapidly proliferating cells may prefer to uptake fatty
acids from the media rather than synthesize them de novo (Yao
et al., 2016a), we next tested whether we could alleviate the
NADPH burden due to fatty acid synthesis by providing cells
with an exogenous source of palmitate. Cells were first grown
in media supplemented with low concentrations of palmitate
(40 mM) conjugated to BSA for 24 hr. Cells were then transferred
to media with the same formulation, but natural-abundance
glucose was replaced with 1,2-13C2 glucose. After 12 hr of labeling, we calculated PPP flux by applying the same method
described above. We found that the addition of exogenous
palmitate to the media reduced PPP flux in both wild-type cells
and IDH1 mutants. However, even when cultured in media
containing exogenous palmitate, PPP flux was higher in IDH1
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mutants relative to wild-type controls (Figure 5C). Additionally,
we found that supplementing HCT116 IDH1 mutants with extracellular palmitate led to the production of 20% more 2-HG
(Figure 5D). This result suggests that decreased palmitate synthesis due to uptake from the media makes more NADPH available for 2-HG synthesis.
Continued Production of 2-HG Sensitizes Cells to
Oxidative Stress
Next, we aimed to test the effect of 2-HG synthesis on the buffering of oxidative stress, which also relies on NADPH. Given
that 2-HG synthesis affects NADPH availability, we hypothesized that it may indirectly limit the ability of a cell to neutralize
an oxidative insult such as hydrogen peroxide (H2O2) or ionizing
radiation (IR). Both H2O2 and IR result in highly reactive free
radicals that damage proteins and DNA (Azzam et al., 2012;
Kuehne et al., 2015). One mechanism to neutralize these reactive oxygen species is the NADPH-dependent glutathione and
thioredoxin systems. Since the glutathione and thioredoxin systems are essential to cell survival upon oxidative stress, we
were interested whether IDH1 mutants would prioritize this
NADPH demand in the presence of H2O2 or IR over the NADPH
demand of 2-HG synthesis, which is not essential for cell
viability.
We first induced oxidative stress by treating IDH1 mutants or
control cells with various concentrations of H2O2 and then
measured cell viability 3 hr later. We found that both HCT116
and astrocyte IDH1 mutants were more sensitive to 1 mM
H2O2 relative to their wild-type controls (Figures 6A and 6B).
As predicted, inhibiting 2-HG synthesis with AGI-5198 improved
cell viability in the presence of H2O2 (Figure S5B).
We then repeated a similar analysis using radiation exposure as the oxidative insult. We treated wild-type cells
and IDH1 mutants with 0, 3, 6, or 9 Gy of IR and measured
cell death 72 or 96 hr after exposure (Figure 6C). Consistent

Figure 5. Synthesis of 2-HG and Palmitate
Compete for NADPH
(A) Relative palmitate levels in wild-type HCT116
cells and R132H/+ mutants.
(B) Isotopologue distribution of palmitoylcarnitine in
HCT116 wild-type and R132H/+ cells after U-13C
glucose labeling.
(C) Providing exogenous palmitate lowers PPP flux
in both R132H/+ and WT HCT116 cells.
(D) Relative 2-HG levels in IDH1 mutants cultured
with and without extracellular palmitate. 2-HG is
significantly elevated when exogenous palmitate is
provided. Data shown are mean values ± SD (n = 3).
*p value < 0.05; ***p value < 0.001.

with our H2O2 results, IDH1 mutants
were significantly more sensitive to IR
than wild-type controls. We next
extended our analysis to HCT116 cells
with a IDH2 mutation substituting an
arginine with a lysine at codon 172
(R172K). Similar to the R132H mutation
in IDH1, the R172K mutation in IDH2
results in an enzyme gain of function where alpha-ketoglutarate is transformed into 2-HG with the simultaneous oxidation
of NADPH to NADP+ (Ward et al., 2010). Unlike IDH1, however, IDH2 is localized to the mitochondrial matrix. IDH2 mutants also showed a significantly increased sensitivity to IR
relative to wild-type HCT116 cells (Figure 6C). Interestingly,
the IDH2 mutants were less sensitive to IR than the IDH1
mutants.
To evaluate the response of the PPP to oxidative stress, we
exposed cells to 1 mM H2O2 for 1 hr while simultaneously labeling them with 1,2-13C2 glucose during the same time period. In
IDH1 mutant cells, we observed significantly less M+2 labeling
in lactate relative to wild-type cells (Figure 6D). Notably, the ratio
of the PPP to glycolysis is significantly larger in the IDH1 mutants
compared to wild types (Figure 6E), suggesting that IDH1 mutants direct more carbon into the PPP and less carbon directly
through glycolysis. To determine the extent to which cells
continue to synthesize 2-HG upon oxidative insult, we treated
IDH1 mutants with 1 mM H2O2 for 3 hr. During this 3-hr period,
we simultaneously labeled the cells with U-13C glucose.
Although 2-HG synthesis from glucose was reduced, it was not
discontinued (Figure 6F). We then repeated the experiment using
U-13C glutamine and obtained similar results (Figure 6G),
showing that 2-HG continues to be synthesized from both
glucose and glutamine during conditions of oxidative stress.
Taken together, our results suggest that the NADPH demand
imposed by continued 2-HG synthesis in the face of oxidative
stress decreases cell viability. Despite the relative increase in
PPP activity, the NADPH produced may be insufficient to support both 2-HG synthesis and the buffering of oxidative stress,
thereby leading to cell death. Alternatively, cell death may be
due to insufficient flux of carbon through glycolysis as a result
of elevated PPP activity. Notwithstanding, the increased NADPH
demand from 2-HG synthesis during oxidative insult is detrimental to cell survival.
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Table 1. ISA Values from Cells Labeled with U-13C Glucose for 24
and 120 hr Show That the Fractional De Novo Synthesis of
Palmitate Is Decreased in R132H/+ Cells
WTa

R132H/+a

WTb

R132H/+b

Dglucose

0.55 ± 0.04

0.54 ± 0.02

0.67 ± 0.01

0.68 ± 0.04

g

0.50 ± 0.05

0.41 ± 0.03

0.77 ± 0.03

0.59 ± 0.07

a

24-hr label time.
b
120-hr label time.

IDH1 Mutants Use More Exogenous Acetate for
Palmitate Synthesis Than Wild-Type Cells
Our data above support that consumption of NADPH for 2-HG
synthesis limits NADPH available for buffering oxidative stress.
We also note that the decrease in PPP flux due to 2-HG inhibition is on the same order of magnitude as the decrease in
PPP flux due to palmitate supplementation (Figures 4B and
5C), suggesting that both processes contribute to PPP flux.
The KM value for NADPH for R132H/+ has been reported
as < 0.4 mM (Pietrak et al., 2011), while the KM value for
NADPH for the overall reaction catalyzed by human fatty
acid synthase has been reported as 5 ± 1 mM (Carlisle-Moore
et al., 2005). These values support that the IDH1 mutant heterodimer binds NADPH more efficiently than fatty acid synthase
at low NADPH concentrations, which are observed in IDH1
mutants (Figures 2B and 2C). In addition to 2-HG production
competing for cytosolic NADPH, we also sought to assess
whether 2-HG production may compete with palmitate synthesis for carbon utilization. Accordingly, we cultured wild-type
cells and IDH1 mutants in media containing U-13C glucose
and 15 mM sodium acetate for 24 hr. We then measured palmitoylcarnitine labeling in each sample and applied ISA (Table
S2). We point out that the addition of sodium acetate
decreased the proliferation rate of both wild-type cells and
IDH1 mutants, thereby preventing the direct comparison of
data in Table 1 to Table S2. Nonetheless, although the values
of Dglucose for wild-type cells and IDH1 mutants were comparable when cultured in normal media, the value of Dglucose
decreased from 0.62 to 0.57 in the presence of exogenous acetate. These results show that IDH1 mutants use exogenous
carbon as a source of acetyl-CoA to a greater extent than
wild-type cells, suggesting that 2-HG synthesis may also
impose limitations on carbon availability.
We attempted to apply a similar experimental design
to that of acetate above by supplementing cells with exogenous reduced glutathione (GSH). Although, in theory, exogenous GSH should reduce cytosolic NADPH demands,
GSH added to media spontaneously oxidized over the time
course of our experiments and therefore could not reliably
be evaluated.
DISCUSSION
Glioma patients with mutations in IDH1 are known to have prolonged survival compared to glioma patients of the same grade
with wild-type enzyme (Labussiere et al., 2010; Li et al., 2013;
Parsons et al., 2008). These different clinical outcomes have
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been associated with increased sensitivity of IDH mutant tumors
to the oxidative stress of cytotoxic therapies (Bleeker et al., 2010;
Houillier et al., 2010; Mohrenz et al., 2013; Tran et al., 2014).
Although the mechanistic basis of this sensitivity has not been
established, substantial evidence suggests that it is related to
an NADPH deficit that affects cellular responses to reactive
oxygen species. Importantly, when tumors with IDH1 mutations
are heterozygous, wild-type enzyme is unable to efficiently produce NADPH (Zhao et al., 2009). In glioblastoma patients, it has
been reported that IDH1 mutations result in about a 2-fold
decrease in NADPH production by wild-type enzyme (Bleeker
et al., 2010). Since wild-type IDH1 is an important source of
NADPH in healthy brain tissue, it has been proposed that
R132H mutations lead to an NADPH deficit due to impaired
wild-type enzyme activity (Molenaar et al., 2015). Prior to the current study, the potential effect of the NADPH consumed by
mutant IDH1 during 2-HG synthesis had not been quantitatively
evaluated.
Here, we show that the actual synthesis of 2-HG creates a
significant NADPH demand that is partially supported by a
40% increase in PPP activity. When mutant IDH1 is pharmacologically inactivated by AGI-5198, PPP activity is reduced
toward wild-type levels. It has been suggested previously
that the NADPH deficit in IDH1 mutants primarily results
from 2-HG inactivating wild-type IDH1 enzyme, thereby preventing its NADPH production (Molenaar et al., 2015). Our
data suggest, however, that the consumption of NADPH during 2-HG synthesis creates a significant NADPH demand
contributing to the NADPH deficit. When we treat wild-type
cells with exogenous 2-HG that accumulates to the same
intracellular level as when synthesized endogenously by
IDH1 mutant cells, we do not observe an increase in PPP activity as we do in IDH1 mutant cells. These results indicate
that NADPH homeostasis is disrupted by 2-HG synthesis, independent of any interaction between 2-HG and wild-type
IDH1 enzyme.
Our data suggest that 2-HG synthesis is regulated by NADPH
availability, which is consistent with what is known about the
regulation of the wild-type IDH enzyme (Leonardi et al., 2012;
Reitman and Yan, 2010). When we increase NADPH availability
by partially relieving the burden of fatty acid synthesis with
exogenous palmitate, 2-HG synthesis is increased by 20%.
Similarly, when cells are exposed to oxidative stress, NADPH
availability is decreased due to elevated activity of NADPHrequiring antioxidant pathways. In this situation, we observe
decreased 2-HG synthesis. Interestingly, although 2-HG synthesis is reduced under conditions of oxidative stress, the
anabolic process still consumes NADPH at a time when
NADPH is critical to neutralize reactive oxygen species.
Even this reduced rate of 2-HG synthesis negatively affects
cell survival. Thus, while 2-HG is not essential for cell viability,
cells continue to consume NADPH for its synthesis in competition with other NADPH-requiring pathways that are essential
for cell viability. Consequently, 2-HG synthesis may represent
a metabolic vulnerability that sensitizes cells to IR. Inhibiting
2-HG synthesis while co-administering radiotherapy could
therefore lead to a worse clinical outcome than radiotherapy
alone.
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Figure 6. Effects of Oxidative Stress on IDH1 and IDH2 Mutant Cells
(A) Cell viability as measured by release of LDH from wild-type or IDH1 mutant astrocytes after H2O2 treatment for 3 hr at the concentrations shown.
(B) Cell viability as measured by release of LDH from wild-type or R132H/+ HCT116 cells after 1 mM H2O2 treatment for 3 hr.
(C) Percent cell viability after 0–9 Gy of IR treatment. Cell viability was measured 72 hr after exposure in HCT116 cells and 96 hr after exposure in astrocytes
(astrocytes did not exhibit signs of cell death at 72 hr).
(D) Isotopologue distribution of lactate after HCT116 R132H/+ cells were incubated in 1,2-13C2 glucose and 1 mM H2O2 for 1 hr.
(E) The ratio of PPP to glycolysis is elevated in wild-type HCT116 cells relative to R132H/+ mutants after exposure to H2O2 for 1 hr.
(F) Isotopologue distribution of 2-HG after HCT116 R132/+ cells were incubated in U-13C glucose with or without 1 mM H2O2 for 3 hr.
(G) Isotopologue distribution of 2-HG after HCT116 R132H/+ cells were incubated in U-13C glutamine, with or without 1 mM H2O2 for 3 hr. Data shown are mean
values ± SD (n = 3). *p value < 0.05; **p value < 0.01.

EXPERIMENTAL PROCEDURES
Materials
All liquid chromatography solvents and additives were obtained from
Sigma-Aldrich (St. Louis, MO) and Honeywell Burdick & Jackson (Morristown, NJ). All cell culture media and reagents were purchased from Thermo
Fisher (Mountain View, CA) or Sciencell (Carlsbad, CA). H2O2 was purchased from Sigma-Aldrich (St. Louis, MO). Human colorectal carcinoma
(HCT116) cells with a heterozygous knockin of IDH1 mutant (R132H)
were obtained from Horizon Discovery (Cambridge, UK). Human immortalized astrocytes were generated as described below. All stable isotopes
were purchased from Cambridge Isotope Laboratories (Tewksbury, MO).
AGI-5198 was purchased from Cayman Chemical (Ann Arbor, MI).
Palmitate-BSA conjugate was purchased from Seahorse Bioscience (Santa
Clara, CA).
Generation of IDH1 Mutant Astrocytes
We serially transduced human fetal astrocytes (Sciencell Research
Laboratories) with pBabe-hygro hTERT (Counter et al., 1998), pBabeNeomycin-DD (dominant-negative allele of p53) (Hahn et al., 2002), and
pMKO-puromycin p16 shRNA (Boehm et al., 2005), in that order. After
each infection, cells were selected with 400 mg/mL hygromycin, 800 mg/mL
G418, or 1.5 mg/mL puromycin. We cultured cells on poly-D-lysine or
poly-L-lysine plates (BD Biosciences) in Astrocyte Media (Sciencell Research
Laboratories).
IDH1-FLAG was cloned using restriction enzyme digestion from the pSLIKIDH1-FLAG plasmid and inserted into the pMIG plasmid. The R132H mutation
was then introduced into the pMIG IDH1-FLAG using the Q5 site-directed

mutagenesis kit (NEB) according to manufacturer’s instructions. pSLIKIDH1-FLAG was a gift from Christian Metallo (Addgene plasmid #66802),
and pMIG was a gift from William Hahn (Addgene plasmid #9044). 8 3 105
293T cells were plated, and the next day retrovirus was generated by transfecting 9 mg of the pMIG IDH1WT or pMIG IDH1R132H plasmids with 1 mg of
pCL Ampho packaging plasmid using Fugene 6 transfection reagent according to manufacturer’s instructions. Media containing the retrovirus was then
collected and filtered using a 0.45-mm filter. 1 3 106 immortalized human astrocytes (HAED16) were plated and the next day transduced with the pMIG
IDH1WT or pMIG IDH1R132H retrovirus. GFP-positive cells were selected using
FACS 72 hr later.
Cell Culture and Sample Preparation
HCT116 cells were grown in McCoy’s 5A Modified Media (Thermo Fisher)
with 10% FBS and no antibiotics, at 37 C and 5% CO2 (unless otherwise
noted). Astrocytes were grown in Astrocyte Media with 2% FBS, 1% astrocyte growth supplement, and 1% penicillin-streptomycin (Sciencell). For all
experiments, cells were plated at a density of 2.0 or 2.5 3 106 cells per plate.
Isotopic labeling experiments were performed in high-glucose DMEM, unless
otherwise noted. Labeling experiments with 1,2-13C2 glucose included 2%
FBS to minimize the concentration of unlabeled glucose. H2O2 experiments
were conducted in media without FBS, as serum contains components that
can act as a protectant against free radicals. Cells were harvested by aspirating media, then washing with PBS three times. This was followed by a
wash with HPLC-grade water, upon which cells were then quenched with
ice-cold HPLC-grade methanol. Cells were scraped from the plate and
collected in methanol, pelleted, and dried via SpeedVac and subsequent
lyophilization.
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Extraction of Metabolites
Cell pellets were extracted with methanol/acetonitrile/water (2:2:1), with solvent volumes normalized to a ratio of 1 mL of solvent per 1 mg of cell pellet.
As previously described (Chen et al., 2016), samples were vortexed for 30 s
and incubated for 1 min in liquid nitrogen, and then sonicated for 10 min.
Following a 1-hr incubation at 20 C, the samples were centrifuged at
14,000 rpm for 10 min. The supernatant was collected and dried via SpeedVac
and reconstituted in acetonitrile/water (1:1). The reconstitution solvent volume
was normalized to a ratio of 100 mL per 1 mg of initial cell pellet.

Astrocytes did not show significant cell death at 72 hr and were assayed at
96 hr with trypan blue.

Determination of PPP Flux
Relative PPP flux was quantified by using 1,2-13C2 glucose as a tracer, as previously described (Lee et al., 1998; Li et al., 2014). For measuring relative PPP
flux and PPP/glycolysis ratios, cells were grown for 24 hr in DMEM with 10%
FBS. Media was then exchanged for DMEM containing 5 mM 1,2-13C2 glucose
and 2% FBS for a 12-hr incubation before cells were harvested. The M+1/M+2
ratio indicates the ratio of glucose cycled through the oxidative PPP to glucose
going directly through glycolysis. We determined PPP flux with the following
formula: relative PPP flux = glucose uptake rate 3 [M+1 lactate/(M+2 lactate +
M+1 lactate)]. Flux was normalized to wild-type cells by setting the wild-type
value equal to 1.

Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2017.12.050.

Measurement of Cell Viability
Cell viability was measured both with a trypan blue exclusion assay as well as a
lactate dehydrogenase (LDH) cytotoxicity assay (Biovision) after exposure to
H2O2. Cells were counted following the trypan blue exclusion assay. The
LDH assay was performed in a 96-well plate, where 1.0 3 105 cells per well
in 200 mL of media were determined to be the optimal target cell number.
Per the user manual, cells were exposed to H2O2 and LDH release was
measured spectrophotometrically at 490 nm.
LC/MS-Based Metabolomics
Metabolite analysis was performed on a Thermo Scientific Q Exactive Plus
Orbitrap connected to a Dionex UltiMate HPLC system (Waltham, MA) in
negative ionization mode with 70,000 resolving power. For each sample,
3 mL was injected onto a Luna Aminopropyl column (3 mm, 150 mm 3
1.0 mm inner diameter [I.D.]; Phenomenex, Torrance, CA) set to a flow rate
of 50 mL/min. Mobile phase A was 95% water, 5% acetonitrile (ACN),
20 mM ammonium hydroxide, and 20 mM ammonium acetate. Mobile
phase B was 95% ACN and 5% water. The column was kept at 30 C for
the duration of the following linear gradient: 0–45 min, 100%–0% B; 45–
50 min, 0% B; 50–51 min, 0%–100% B; 51–60 min, 100% B (isocratic).
Analysis of fatty acids was performed on an Agilent 6530 Q-TOF using an
electrospray ionization (ESI) source with Agilent Jet Stream Technology.
Mass range was set to 100–1,500 m/z in positive ionization mode. Aliquots
of 2 mL of sample were injected onto a CORTECS UPLC T3 column
(1.6 mm, 150 mm 3 2.1 mm I.D.; Waters Corporation, Milford, MA) connected
to an Agilent 1290 Infinity UHPLC system (Santa Clara, CA) with a flow rate of
200 mL/min. Mobile phase A was 100% water, 5 mM ammonium acetate, and
5 mM ammonium phosphate. Mobile phase B was 90% isopropanol, 10%
methanol, 5 mM ammonium acetate, and 5 mM ammonium phosphate. The
column was maintained at 55 C for the duration of the following linear
gradient: 0–36 min, 0%–100% B; 36–40 min, 100% B (isocratic); 40–
45 min, 100%–0% B.
Metabolite Quantification
Glucose uptake and lactate secretion rates were determined by using an Agilent Q-TOF (6530) connected to an Agilent 1260 HPLC system (Santa Clara,
CA) in negative ionization mode, as described above. 2-HG production flux
was measured by quantitating media 2-HG levels over 24 hr. NADPH levels
were measured with a NADP+/NADPH Quantification kit (BioVision) and a
BioTek Cytation 5 plate reader (Winooski, VT).
Radiation Exposure
Cells were pulsed with 0, 3, 6, and 9 Gy of IR by using a Precision X-Ray
(North Bradford, CT) X-RAD 320 biological irradiator. HCT116 cell death was
measured with a trypan blue exclusion assay 72 hr after radiation exposure.
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Statistical Analysis
All experiments were performed in triplicate (n = 3). All p values were calculated
with a two-tailed Student’s paired t test.
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